Congenital adrenal hyperplasia caused by 11β-hydroxylase deficiency — the second most common form of CAH, accounting for 5–8% of all CAH cases, caused by autosomal recessive mutations in the CYP11B1 gene encoding the mitochondrial enzyme 11β-hydroxylase (CYP11B1), which catalyzes the final hydroxylation step converting 11-deoxycortisol to cortisol and 11-deoxycorticosterone (DOC) to corticosterone in the zona fasciculata — presents with a paradoxical biochemical phenotype that sharply distinguishes it from the far more common 21-hydroxylase-deficient CAH: because CYP11B1 deficiency leaves the mineralocorticoid pathway partially intact (DOC, a potent mineralocorticoid, accumulates in extraordinary quantities), affected individuals develop sodium retention and hypertension rather than the salt-wasting crisis of classic 21-OHD, making CYP11B1-CAH one of the endocrine causes of secondary hypertension in children; simultaneously, the cortisol deficiency drives compensatory ACTH hypersecretion that floods the intact androgen pathway with precursors — 11-deoxycortisol, DHEA, DHEA-S, androstenedione, and testosterone accumulate — causing virilization of 46,XX females (ranging from mild clitoromegaly at Prader stage 2 to severe ambiguous genitalia at Prader stages 4–5 presenting as 46,XX DSD at birth), isosexual precocious puberty with accelerated linear growth and advanced bone age in affected males, and advanced bone age in all affected individuals that threatens final adult height even with adequate treatment; glucocorticoid replacement with hydrocortisone is the cornerstone of treatment, normalizing ACTH, reducing DOC accumulation, and suppressing androgen excess, with the target being suppression of 11-deoxycortisol and 11-deoxycorticosterone into the normal range while maintaining androstenedione and testosterone in the age-appropriate prepubertal range, blood pressure in the normal range for age and sex, and growth velocity appropriate for chronological age; fludrocortisone is not typically required because DOC-mediated mineralocorticoid excess rather than aldosterone deficiency defines the mineralocorticoid phenotype of CYP11B1-CAH; genital reconstructive surgery is considered for severely virilized 46,XX females in collaboration with pediatric urology or gynecology; molecular confirmation by CYP11B1 sequencing identifies the causative mutations with implications for prenatal diagnosis and family cascade testing.
CYP11B1-CAH technology platforms — encompassing the pediatric endocrinology scheduling and electronic health record platforms where specialist physicians titrate hydrocortisone based on serial 11-deoxycortisol and androstenedione measurements, the ambulatory blood pressure monitoring systems tracking the hypertension that is the cardinal mineralocorticoid manifestation of CYP11B1 enzyme deficiency, the hormonal monitoring laboratory platforms measuring 11-deoxycortisol, 11-deoxycorticosterone, androstenedione, and testosterone to guide dose adjustment, the bone age and growth velocity surveillance platforms detecting the auxological consequences of androgen excess and glucocorticoid overtreatment, the DSD multi-disciplinary coordination platforms connecting endocrinology, urology and gynecology, psychology, and genetics for virilized females, the adrenal crisis emergency alert and sick-day protocol platforms ensuring families know that stress dosing is essential despite the non-salt-wasting phenotype, and the antihypertensive medication tracking platforms monitoring blood pressure response to glucocorticoid therapy and adjunctive antihypertensive agents — must maintain the availability and performance standards required by the hypertension monitoring imperative, the serial 11-deoxycortisol monitoring frequency, and the DSD multi-disciplinary coordination complexity that define modern CYP11B1-CAH management. This guide explains why CYP11B1-CAH tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the blood pressure surveillance, androgen suppression monitoring, adrenal crisis prevention, and DSD care coordination requirements of the second most common form of congenital adrenal hyperplasia.
Why CYP11B1-CAH Tech Platforms Require Specialized Monitoring Attention
CYP11B1-CAH management is defined by several challenges that distinguish it from the more common 21-OHD and demand specialized platform availability: the hypertension monitoring imperative — DOC-mediated mineralocorticoid hypertension in CYP11B1-CAH can be severe, affecting up to 70% of patients at diagnosis, causing target organ damage including left ventricular hypertrophy and retinopathy if uncontrolled, requiring ambulatory blood pressure monitoring, antihypertensive tracking, and documentation of blood pressure response to glucocorticoid dose adjustment since hydrocortisone-mediated ACTH suppression reduces DOC accumulation and normalizes blood pressure in most but not all patients; the androgen suppression monitoring requirement — serial 11-deoxycortisol, 11-deoxycorticosterone, androstenedione, and testosterone measurements are the biochemical markers of disease activity in CYP11B1-CAH, and the therapeutic window for hydrocortisone dosing is narrow because underdosing allows continued androgen excess causing advancing virilization and bone age while overdosing causes iatrogenic Cushing syndrome and growth suppression; the adrenal crisis prevention imperative — though CYP11B1-CAH does not cause salt-wasting, cortisol deficiency still places patients at risk for adrenal crisis under physiological stress, requiring sick-day protocol adherence and emergency hydrocortisone access; and the DSD multi-disciplinary coordination complexity for virilized 46,XX females, requiring joint management across endocrinology, urology or gynecology, psychology, and genetics.
Ambulatory blood pressure monitoring platforms are the primary surveillance tool for the defining complication of CYP11B1-CAH. DOC-mediated hypertension requires ambulatory blood pressure log tracking, antihypertensive medication adherence documentation, and blood pressure response to hydrocortisone dose adjustment. Monitor blood pressure monitoring platforms at 1-minute intervals during clinical hours.
Serial hormonal monitoring platforms guide the therapeutic window between androgen suppression and glucocorticoid overtreatment. 11-deoxycortisol, 11-deoxycorticosterone, androstenedione, and testosterone measurements at every endocrinology visit are the biochemical markers that prevent both undertreated virilization and iatrogenic Cushing. Monitor hormonal monitoring platforms at 1-minute intervals during clinical hours.
Adrenal crisis emergency platforms are essential despite the non-salt-wasting phenotype. Cortisol deficiency in CYP11B1-CAH places patients at risk for stress-induced adrenal crisis under surgical, febrile, or traumatic stress, requiring sick-day protocol access and emergency IM hydrocortisone availability. Monitor emergency protocol platforms at 1-minute intervals, 24/7.
DSD multi-disciplinary coordination portals manage the complex care of virilized 46,XX females. Surgical planning, psychological support, gender identity counseling, and genetic cascade testing require platform availability across specialties. Monitor multi-disciplinary coordination portals at 1-minute intervals during clinical hours.
Bone age and growth monitoring systems track the auxological consequences of androgen excess. Advanced bone age from androgen excess threatens final adult height; growth velocity deceleration indicates glucocorticoid overtreatment. Monitor growth surveillance platforms at 1-minute intervals during clinical hours.
What to Monitor on a CYP11B1-CAH Tech Platform
Ambulatory Blood Pressure Monitoring and Antihypertensive Tracking
Monitor ambulatory blood pressure log records (24-hour ABPM studies at diagnosis and every 6–12 months — mean daytime and nighttime systolic and diastolic blood pressure, non-dipping pattern documentation, blood pressure load above the 95th percentile for age, sex, and height), antihypertensive medication tracking records (calcium channel blocker or ACE inhibitor prescription for blood pressure not normalized by hydrocortisone alone — amlodipine or enalapril dosing, adherence documentation, blood pressure response to antihypertensive initiation), blood pressure response to hydrocortisone dose adjustment records (blood pressure trend correlated with 11-deoxycorticosterone level trend — DOC-mediated hypertension resolves with adequate ACTH suppression in most patients, providing both biochemical and clinical confirmation of adequate glucocorticoid replacement), echocardiogram records (left ventricular hypertrophy surveillance in hypertensive patients — LVH prevalence and regression with blood pressure normalization), and ophthalmologic examination records (hypertensive retinopathy surveillance in patients with prolonged poorly controlled hypertension before diagnosis) at 1-minute intervals during clinical hours. Alert immediately — ambulatory blood pressure monitoring platform failures prevent the quarterly blood pressure load assessment for a 10-year-old male with CYP11B1-CAH whose blood pressure at the last visit was 142/90 mmHg on amlodipine 5 mg daily, delaying the dose adjustment review that determines whether blood pressure target organ protection is adequate.
Serial Hormonal Monitoring: 11-Deoxycortisol, DOC, and Androgen Suppression
Monitor serum 11-deoxycortisol result records (the primary disease activity marker in CYP11B1-CAH — target below 50 ng/dL indicating adequate 11β-hydroxylase suppression via ACTH reduction; 11-deoxycortisol >200 ng/dL indicating undertreated ACTH excess driving androgen precursor accumulation), 11-deoxycorticosterone result records (DOC — the mineralocorticoid responsible for hypertension; target below 20 ng/dL; DOC >50 ng/dL correlating with hypertension severity and antihypertensive requirement), androstenedione and testosterone result records (androstenedione and testosterone in the age-appropriate prepubertal range confirming adequate androgen suppression; elevated androstenedione confirming breakthrough androgen excess from inadequate ACTH suppression), ACTH result records (morning ACTH confirming suppression of hypothalamic-pituitary-adrenal axis hyperstimulation — target in the low-normal to mid-normal range), and DHEA-S result records (DHEA-S as a supplementary adrenal androgen marker in pubertal and post-pubertal patients) at 1-minute intervals during clinical hours. Alert immediately — hormonal monitoring laboratory platform failures prevent the 3-month 11-deoxycortisol result from being processed for an 8-year-old female with CYP11B1-CAH whose androstenedione was 180 ng/dL at the last visit — double the upper limit for her Tanner stage — and who requires an urgent hydrocortisone dose increase that cannot be implemented without the confirmatory 11-deoxycortisol measurement.
Hydrocortisone Adherence and Dose Titration
Monitor hydrocortisone prescription and dispensing records (dose in mg/m²/day — target 10–15 mg/m²/day divided in two to three daily doses; dose above 15 mg/m²/day increasing iatrogenic Cushing risk; pharmacy dispensing frequency confirming adherence), morning hydrocortisone administration timing records (morning dose administered within 30 minutes of waking to capture the early morning ACTH surge — adherence to morning timing essential for 17-OHP and 11-deoxycortisol measurement validity), dose adjustment documentation records (increase by 10–15% increments for breakthrough 11-deoxycortisol or androstenedione elevation; reduction by 10–15% increments for signs of over-replacement — weight gain, striae, growth deceleration), hydrocortisone formulation records (immediate-release hydrocortisone versus modified-release preparations — Chronocort or Alkindi Sprinkle dosing in infants and young children for precise low-dose dispensing), and cortisol day curve records (7-point salivary or serum cortisol profiles at selected visits to assess adequacy of cortisol exposure across the day without over-replacement) at 1-minute intervals during clinical hours.
Adrenal Crisis Risk Assessment and Sick-Day Protocol
Monitor sick-day protocol documentation records (written sick-day instructions in patient portal: for fever above 38.5°C, vomiting, major injury, or surgical procedure — double or triple the daily hydrocortisone dose; for inability to take oral medication or repeated vomiting — administer emergency intramuscular hydrocortisone injection kit), emergency hydrocortisone prescription records (Solu-Cortef Act-O-Vial 100 mg kit — prescription validity, pharmacy dispensing confirmation, kit expiry tracking, replacement prescription scheduling), intercurrent illness stress dosing records (family-documented stress dosing events and adrenal crisis near-misses, tracked at follow-up visits), medical alert identification records (MedicAlert bracelet or equivalent — "Adrenal Insufficiency — Needs Hydrocortisone" — worn at all times), and perioperative stress dosing coordination records (surgical stress dose protocol communicated to anesthesiology and surgical teams before any elective procedure) at 1-minute intervals, 24/7. Alert immediately — adrenal crisis emergency protocol portal failures when the family of a 6-year-old with CYP11B1-CAH accesses the patient portal at midnight to confirm the sick-day dosing instructions during a febrile illness — and finds the portal unavailable — convert a manageable stress dosing scenario into an unnecessary emergency department visit.
Cortisol Levels and Adrenal Insufficiency Documentation
Monitor random cortisol result records (serum cortisol at the time of 11-deoxycortisol and androstenedione measurements — confirming that measured cortisol is detectable and consistent with adequate glucocorticoid replacement rather than cortisol deficiency), stimulation test records (ACTH stimulation test at diagnosis confirming inability to mount a cortisol response above 18 µg/dL — confirming primary adrenal insufficiency from the enzymatic block; reserved for diagnostic uncertainty rather than routine monitoring), and adrenal crisis event records (emergency department visits, hospitalizations, or documented physiological stress events with adrenal crisis features — hypotension, hypoglycemia, altered consciousness requiring parenteral hydrocortisone) at 1-minute intervals during clinical hours.
Bone Age Assessment and Growth Velocity
Monitor bone age radiograph records (left hand and wrist bone age by Greulich-Pyle atlas at diagnosis and annually — bone age advancement more than 2 years above chronological age indicating androgen excess causing premature epiphyseal maturation; bone age consistent with chronological age confirming adequate androgen suppression), height and weight records (growth velocity at every endocrinology visit — height velocity above the 97th percentile for chronological age indicating androgen excess; height velocity below the 25th percentile indicating glucocorticoid overtreatment or GH deficiency), predicted adult height records (bone age-corrected adult height prediction by Bayley-Pinneau method — predicted height deficit below mid-parental target height triggering endocrine review), and GnRH analog records (in patients with gonadotropin-independent precocious puberty and rapidly advancing bone age — GnRH agonist use to slow bone age advancement while optimizing glucocorticoid control) at 1-minute intervals during clinical hours.
Genital Examination and DSD Management Documentation
Monitor genital examination records (Prader staging for virilized 46,XX females — clitoral length, labial fusion, urogenital sinus documentation; annual Müllerian anatomy assessment by pelvic ultrasound), DSD multi-disciplinary team records (joint decisions by endocrinology, pediatric urology or gynecology, psychology, and genetics — surgical timing discussion documentation, patient and family counseling records, surgical outcome tracking), psychosocial assessment records (gender identity development, body image, disclosure counseling, peer support referrals — sensitive psychological health records requiring heightened privacy controls), and CYP11B1 molecular genetic testing records (gene sequencing confirming causative mutations — mutation type correlates with disease severity and guides recurrence risk counseling; autosomal recessive inheritance pattern with 25% recurrence risk in future pregnancies) at 1-minute intervals during clinical hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. CYP11B1-CAH management coordinates across pediatric endocrinology (hormonal monitoring and dose titration), cardiology or nephrology (blood pressure management and antihypertensive coordination), radiology (ambulatory blood pressure and bone age), pediatric urology or gynecology (DSD surgical planning), psychology (gender identity and body image counseling), genetics (CYP11B1 molecular analysis and family cascade testing), pharmacy (hydrocortisone, antihypertensives, emergency IM kit), and emergency medicine (adrenal crisis management) — authentication failures disrupt every team member required to execute the DOC hypertension monitoring, androgen suppression titration, and DSD care coordination that define CYP11B1-CAH management.
SSL Certificates
Monitor SSL certificate expiry across all endocrinology scheduling portals, hormonal monitoring laboratory platforms, blood pressure tracking systems, adrenal crisis emergency protocol portals, DSD coordination platforms, and pharmacy dispensing systems. Certificate errors disrupt emergency protocol access and sick-day rule document availability at the moments when families most urgently need them.
HIPAA and CYP11B1-CAH Patient Privacy Considerations
CYP11B1-CAH technology platforms handle PHI of exceptional sensitivity — including molecular CYP11B1 genetic testing results (autosomal recessive, with 25% recurrence risk and 50% carrier probability for siblings — genetic information subject to GINA protections), genital examination documentation and surgical records for virilized 46,XX females (psychosocially sensitive, requiring strict access controls), gender identity counseling and psychosocial assessment records, blood pressure and antihypertensive medication records, and hormonal monitoring results linking adrenal steroidogenesis biochemistry to DSD phenotype. The intersection of genetic information, DSD diagnosis, and gender identity documentation in CYP11B1-CAH records demands access controls, audit logging, and minimum necessary disclosure standards that exceed standard PHI handling.
Alerting Strategy for CYP11B1-CAH Tech Platforms
Immediate 24/7 alerting for adrenal crisis emergency platforms: Sick-day protocol portals, emergency IM hydrocortisone kit dispensing records, and emergency department clinical decision support. CYP11B1-CAH causes cortisol deficiency — adrenal crisis risk under physiological stress is real despite the non-salt-wasting phenotype.
Immediate clinical-hours alerting for blood pressure monitoring platforms: Ambulatory blood pressure log, antihypertensive tracking, and blood pressure response to hydrocortisone dose adjustment — the primary cardiovascular complication surveillance in CYP11B1-CAH.
Immediate clinical-hours alerting for hormonal monitoring platforms: 11-deoxycortisol, DOC, androstenedione, testosterone, and ACTH measurements guiding the therapeutic window.
Immediate clinic-hours alerting for DSD multi-disciplinary coordination portals: Genital reconstructive surgery planning, psychology coordination, and genetics for virilized 46,XX females.
Immediate clinical-hours alerting for bone age and growth surveillance: Annual bone age radiograph ordering and growth velocity tracking.
Sustained-failure alert (10–15 minutes): Patient registry, CYP11B1 molecular genetic testing, and adult long-term surveillance platforms.
30-day advance warning: SSL certificates across all domains, with priority for adrenal crisis emergency protocol portals and blood pressure monitoring systems.
Vigilmon's multi-region monitoring confirms CYP11B1-CAH platform availability from the geographies where pediatric endocrinology centers of excellence, DSD programs, and hypertension specialty clinics concentrate.
Status Page for CYP11B1-CAH Care Team Communication
A real-time status page gives pediatric endocrinologists titrating hydrocortisone against 11-deoxycortisol and blood pressure, cardiologists or nephrologists managing DOC-mediated hypertension, DSD multi-disciplinary team members planning surgical and psychological care, radiologists performing bone age and ABPM studies, pharmacists dispensing hydrocortisone and antihypertensive agents, and emergency physicians managing adrenal crisis immediate platform visibility.
Include the status page URL in adrenal crisis sick-day protocol documents distributed to families, antihypertensive dose adjustment communication records, and DSD multi-disciplinary clinic coordination workflows.
Vigilmon Setup for CYP11B1-CAH Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Adrenal crisis emergency protocol portal (sick-day rules, IM kit instructions) | 1 min | Slack + PagerDuty (24/7) | | Ambulatory blood pressure monitoring platform | 1 min | Slack + PagerDuty (clinical hours) | | Antihypertensive medication tracking | 1 min | Slack + PagerDuty (clinical hours) | | Serum 11-deoxycortisol monitoring | 1 min | Slack + PagerDuty (clinical hours) | | 11-deoxycorticosterone (DOC) level monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Androstenedione and testosterone monitoring | 1 min | Slack + PagerDuty (clinical hours) | | ACTH and cortisol monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Hydrocortisone dose adjustment documentation | 1 min | Slack + PagerDuty (clinical hours) | | Emergency hydrocortisone IM kit prescription and dispensing | 1 min | Slack + PagerDuty (24/7) | | Bone age radiograph ordering system | 1 min | Slack + PagerDuty (radiology hours) | | Growth velocity monitoring (height/weight percentile) | 1 min | Slack + PagerDuty (clinical hours) | | DSD multi-disciplinary coordination portal | 1 min | Slack + PagerDuty (clinic hours) | | Genital examination and surgical planning records | 1 min | Slack + PagerDuty (clinic hours) | | Psychology and gender identity counseling coordination | 2 min | Slack + PagerDuty (clinic hours) | | CYP11B1 molecular genetic testing platform | 2 min | Slack (business hours) | | Patient registry | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure adrenal crisis emergency protocol portal with 24/7 immediate alerting — adrenal crisis risk is real in CYP11B1-CAH despite the non-salt-wasting phenotype
- Add ambulatory blood pressure monitoring platform with immediate clinical-hours alerting — hypertension is the cardinal mineralocorticoid complication of CYP11B1-CAH
- Configure antihypertensive medication tracking with immediate clinical-hours alerting
- Add serum 11-deoxycortisol monitoring with immediate clinical-hours alerting
- Configure 11-deoxycorticosterone (DOC) level tracking with immediate clinical-hours alerting
- Add androstenedione and testosterone monitoring with immediate clinical-hours alerting
- Configure ACTH and cortisol monitoring platforms with immediate clinical-hours alerting
- Add hydrocortisone dose adjustment documentation with immediate clinical-hours alerting
- Configure emergency hydrocortisone IM kit prescription and pharmacy dispensing with 24/7 immediate alerting
- Add bone age radiograph ordering system with immediate radiology-hours alerting
- Configure growth velocity monitoring with immediate clinical-hours alerting
- Add DSD multi-disciplinary coordination portal with immediate clinic-hours alerting
- Configure psychology and gender identity counseling coordination platforms with sustained-failure alerting
- Add CYP11B1 molecular genetic testing platform with sustained-failure alerting
- Enable SSL certificate monitoring across all platforms, prioritizing adrenal crisis emergency protocol portals and blood pressure monitoring systems
- Add the status page URL to sick-day protocol documents distributed to families and emergency departments
Conclusion
CYP11B1-CAH technology platforms are embedded in clinical decisions where blood pressure monitoring platform availability when the pediatric endocrinologist reviews the quarterly ambulatory blood pressure report for a 12-year-old female with CYP11B1-CAH — discovering a mean daytime systolic blood pressure of 148 mmHg on calcium channel blocker monotherapy, with left ventricular hypertrophy on last echocardiogram, requiring an urgent antihypertensive dose escalation and endocrinology review of whether 11-deoxycorticosterone suppression is adequate on the current hydrocortisone regimen — cannot be disrupted by platform failures that delay the blood pressure data review and the coordinated antihypertensive and hormonal dose adjustment that together address the mineralocorticoid excess driving the child's end-organ hypertension; where hormonal monitoring platform availability when the 11-deoxycortisol result for a 7-year-old male with CYP11B1-CAH returns at 340 ng/dL — six times the target — confirming that the current hydrocortisone dose is insufficient to suppress ACTH and that androgen excess is continuing to advance the bone age that has already reached 11 years in a child with a chronological age of 7 — cannot be disrupted by laboratory platform failures that delay the result and the urgent dose increase that would arrest bone age progression; and where adrenal crisis emergency protocol availability at 3:00 AM when the parent of a 5-year-old with CYP11B1-CAH accesses the patient portal to confirm the stress dosing instructions for a child who has been vomiting for 6 hours with a fever and cannot keep oral hydrocortisone down — cannot be disrupted by portal failures that leave the family without the sick-day protocol at the moment when prompt intramuscular hydrocortisone administration determines whether the child develops physiological decompensation from cortisol-deficient stress response. An ambulatory blood pressure platform unavailable when DOC-mediated hypertension is progressing toward end-organ damage, a hormonal monitoring platform that cannot process the 11-deoxycortisol result that would prompt an urgent hydrocortisone dose increase, an adrenal crisis emergency portal unavailable when a family needs stress dosing instructions at 3:00 AM — these are not IT incidents. They are clinical disruptions in the management of a rare endocrine disorder whose hypertension severity, androgen excess auxological consequences, adrenal crisis cortisol deficiency risk, and DSD multi-disciplinary coordination complexity make blood pressure surveillance and hormonal monitoring the twin biochemical lifelines that protect every CYP11B1-CAH patient from the compounding jeopardy of DOC-mediated cardiovascular damage, androgen-driven final height loss, and cortisol-deficient stress response vulnerability.
Uptime monitoring gives CYP11B1-CAH tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to pediatric endocrinology centers, DSD programs, hypertension specialty clinics, and compliance auditors that platform operational reliability matches the blood pressure monitoring urgency, androgen suppression monitoring precision, and adrenal crisis prevention imperative of modern CYP11B1-CAH management.
Start monitoring your CYP11B1-CAH care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #congenital #adrenal #hyperplasia #CAH #CYP11B1 #11betahydroxylase #11deoxycortisol #DOC #hypertension #androgen #virilization #DSD #hydrocortisone #adrenacrisis #sickday #stressdosing #bonage #pediatric #endocrinology #HIPAA #healthtech #digitalhealth #uptime #sre